Inclusion Criteria:  Aged 65-79; Isolated systolic hypertension (office systolic blood pressure (SBP) ≥ 130 and < 150 mmHg and office diastolic blood pressure (DBP) < 80 mmHg) in untreated patients； Ability to understand the study requirements and provide informed consent.  Exclusion Criteria:  Hypersensitivity history to any study drug or similar drug； Severe renal insufficiency (eGFR < 30 mL/min/1.73m2); Hyperkalemia (serum potassium > 5mmol/L); Active liver disease or hepatic insufficiency (AST or ALT > 3 times upper limit of normal); History of malignancy over the past 5 years; Severe disease patients with life expectancy of < 1 year; Previous or current diagnosis of heart failure; Stroke or myocardial infarction within 6 months; Previous or current atrial fibrillation, frequent ventricular premature beats, supraventricular tachycardia; Patients who are receiving other study drugs or study medical devices; Pregnant or lactating women; Other circumstances that patients are not appropriate for the study upon the investigator's judgment.